Two Sigma Advisers’s Seelos Therapeutics, Inc. Common Stock SEEL Stock Holding History

Two Sigma Advisers’s Portfolio SEEL Stock Details SEEL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-50	Closed	-$198K	–	2739
2022 Q3	$198K	Sell	50 -105	-68%	-$413K	﹤0.01%	2205
2022 Q2	$405K	Sell	155 -139	-47%	-$362K	﹤0.01%	2009
2022 Q1	$944K	Sell	294 -89	-23%	-$383K	﹤0.01%	1669
2021 Q4	$2.4M	Sell	383 -78	-17%	-$599K	0.01%	1101
2021 Q3	$4.27M	Buy	461 +210	+84%	+$1.8M	0.01%	865
2021 Q2	$2.54M	Buy	+251	New	+$4.12M	0.01%	1180
2021 Q1	–	Sell	-8	Closed	-$49K	–	2761
2020 Q4	$49K	Sell	8 -22	-73%	-$86.3K	﹤0.01%	2322
2020 Q3	$109K	Buy	+30	New	+$108K	﹤0.01%	2267

Other funds holding SEEL

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GJL

Gendell Jeffrey L $7.34B AUM 183.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

UIC

Uniplan Investment Counsel Milwaukee, Wisconsin $974M AUM 21.37% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

MCM

MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return

MWM

Modera Wealth Management Westwood, New Jersey $8.34B AUM 19.68% 1-Year Est. Return

OMC

Oasis Management Company Grand Cayman, Cayman Islands $1.72B AUM 32.1% 1-Year Est. Return

Two Sigma Advisers's SEEL Position: Q4 2022 in Review

Two Sigma Advisers sold out of Seelos Therapeutics, Inc. Common Stock (SEEL) in Q4 2022, closing a stake of 50 shares — an estimated $198K sold.

Two Sigma Advisers first reported a position in SEEL in Q3 2020 and held it in 8 quarters. The position peaked at $4.27M in Q3 2021. 63 funds tracked by Wall St. Rank hold SEEL as of Q4 2022.

Two Sigma Advisers reported no remaining Seelos Therapeutics, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
Two Sigma Advisers sold 50 Seelos Therapeutics, Inc. Common Stock shares in Q4 2022, an estimated $198K.
Two Sigma Advisers first reported a position in Seelos Therapeutics, Inc. Common Stock in Q3 2020 and held it in 8 quarters.
Two Sigma Advisers's Seelos Therapeutics, Inc. Common Stock position peaked at $4.27M in Q3 2021.
63 funds tracked by Wall St. Rank held Seelos Therapeutics, Inc. Common Stock as of Q4 2022.

Based on Two Sigma Advisers's 13F filing for Q4 2022, filed 14 Feb 2023.